Mucopolysaccharidosis type I is a recessive genetic disease caused by deficiency of the lysosomal enzyme a-L-iduronidase, which leads to a neurodegenerative and systemic disease called Hurler syndrome in its most severe form. Several clinical trials are evaluating adeno-associated virus serotype 9 (AAV9) for the treatment of neurodegenerative diseases. Although these trials focus on systemic or lumbar administration, intrathecal administration via suboccipital puncture into the cisterna magna has demonstrated remarkable efficacy in large animals. We, therefore, conducted a good laboratory practicecompliant non-clinical study to investigate the safety of suboccipital AAV9 gene transfer of human a-L-iduronidase into nonhuman primates. We dosed 22 rhesus macaques, including three immunosuppressed animals, with vehicle or one of two doses of vector. We assessed in-life safety and immune responses. Animals were euthanized 14, 90, or 180 days post-vector administration and evaluated for histopathology and biodistribution. No procedure-related lesions or adverse events occurred. All vector-treated animals showed a dose-dependent mononuclear pleocytosis in the cerebrospinal fluid and minimal to moderate asymptomatic degeneration of dorsal root ganglia neurons and associated axons. These studies support the clinical development of suboccipital AAV delivery for Hurler syndrome and highlight a potential sensory neuron toxicity that warrants careful monitoring in first-in-human studies.
INTRODUCTION
Mucopolysaccharidosis type I (MPS I) is a rare inherited disorder caused by mutations in the gene encoding a-L-iduronidase (IDUA), a lysosomal enzyme required for degradation of glycosaminoglycans, including heparan sulfate and dermatan sulfate. IDUA deficiency results in accumulation of these glycosaminoglycan substrates in cells throughout the body, leading to a diverse array of clinical manifestations. Hepatosplenomegaly, bone deformities, corneal clouding, and cardiac valve stenosis or insufficiency are common complications. 1, 2 Patients with mutations that yield little or no residual expression of active IDUA present with a severe form of the disease, termed Hurler syndrome. In addition to the somatic manifestations of the disease described above, Hurler syndrome is characterized by marked lysosomal storage lesions in the CNS and progressive cognitive impairment beginning in early childhood. 1, 3 Two treatment options are currently available for MPS I. Both are based on the discovery of mannose-6-phosphate receptor-mediated transport of lysosomal enzymes, which allows for extracellular IDUA to undergo endocytosis and trafficking to the lysosome. 4, 5 Intravenous enzyme replacement therapy can deliver the enzyme to most tissues and improves many of the systemic manifestations of the disease. [6] [7] [8] However, intravenous delivery of IDUA does not achieve significant CNS penetration and does not attenuate cognitive decline in the severe Hurler syndrome. 9 In contrast, hematopoietic stem cell transplantation can achieve enzyme delivery to the CNS, as some donor-derived macrophage progenitor cells migrate into the brain, where they secrete IDUA. 10 However, stem cell transplantation is associated with morbidity and mortality, and typically accomplishes incomplete preservation of cognitive function, likely because of limited enzyme delivery to the brain and the slow kinetics of donor cell engraftment in the CNS. 11 With the goal of safely and rapidly reconstituting therapeutic levels of IDUA activity in the CNS, we developed an approach in which the IDUA coding sequence expressed from a strong ubiquitous promoter is delivered to cells throughout the CNS using an adeno-associated virus (AAV) vector injected into the cerebrospinal fluid (CSF). Preclinical studies in naturally occurring canine and feline models of MPS I demonstrated that a single minimally invasive injection of an AAV serotype 9 (AAV9) vector into the cisterna magna (ICM) can achieve high levels of IDUA activity in the CSF within a week of administration, leading to the resolution of storage lesions throughout the brain. [12] [13] [14] The ICM approach results in superior CNS distribution of AAV vectors compared with other routes of CSF access but is not commonly utilized in clinical practice, 15 necessitating the evaluation of the safety of the procedure in preclinical studies.
In order to advance this approach to the clinic, we performed a good laboratory practice-compliant toxicology study in adult rhesus macaques. The use of nonhuman primates was essential for this study, as the size and anatomy of these animals enabled us to utilize the same image-guided ICM delivery approach that will be employed in clinical studies. Furthermore, nonhuman primates better recapitulate host innate and adaptive immune responses to vector and transgene-derived IDUA that are likely to be seen in humans. The size and anatomic similarity of nonhuman primates to humans also make them a relevant model to evaluate vector biodistribution after ICM injection and any toxicity associated with vector delivery to target cells.
RESULTS

Study Design
In this study, we utilized two experimental designs to evaluate the safety, biodistribution, and pharmacology of a vector encoding human IDUA (hIDUA) for up to 180 days after administration by image-guided ICM suboccipital puncture in rhesus macaques (see Table 1 for study design). We evaluated a high dose (HD) of 1 Â 10 13 genome copies (GCs; n = 15) at three different time points (14, 90 , and 180 days postinjection) and a low dose (LD) of 1 Â 10 12 GCs (n = 3; 90 days postinjection) compared with vehicle control (n = 4). Three HD subjects from the 90-day cohort also received immunosuppression (IS) consisting of mycophenolate mofetil (MMF) and rapamycin ( Table 2 ).
In-Life Safety Parameters
We performed sample collection and necropsies at the time points indicated in Table 2 . No adverse events occurred during the administration procedure, and all animals recovered uneventfully from anesthesia. Animals from both studies survived until their scheduled necropsy time point at days 14, 90, or 180 post-vector administration. We did not observe any abnormalities during the course of the study in animals that received the test article in terms of cage-side observations, temperature, heart rate, or respiratory rate (recorded in sedated animals).
The IS regimen administered to three animals caused adverse effects of decreased appetite, diarrhea, and weight loss that all started prior to test article administration. Most affected animals had culture or PCR testing of stools positive for Campylobacter spp. and Helicobacter spp. We provided symptomatic and supportive care, as well as antibiotic treatments (trimethoprim and sulfamethoxazole, erythromycin, or enrofloxacin based on cultures and response to treatment), to control the gastrointestinal symptoms. One animal (RA1404) did not respond to treatment; therefore, the study veterinarian decided to stop MMF on day 35, leading to complete resolution of the symptoms.
All non-IS animals maintained normal body weights throughout the studies (Tables S1 and S2 ). Two IS animals (RA1528 and RA1404) started losing weight soon after the IS regimen was started, before vector dosing. We attributed the cause to repeated episodes of diarrhea and decreased appetite either directly related to the IS drugs, the daily orogastric tubing procedure used to administer the IS drugs, opportunistic enteric pathogens, or a combination of the above.
Pathology
Pathology consisted of complete blood cell (CBC) count, blood chemistry and electrolyte panels, a coagulation panel (thromboplastin time, activated partial thromboplastin time, fibrinogen, D-dimer, and fibrin degradation products), CSF white blood cell (WBC) count, glucose and protein levels, and cytosmear analysis (Figure S1 and data not shown). We have presented only the parameters with test articlerelated abnormalities, defined as modifications that (1) exceeded the baseline average ±2 SDs; (2) occurred after administering the test article; and (3) were not observed in the control group. Among non-IS animals, we did not find any significant abnormalities in the CBC, blood chemistry (including transaminases), or coagulation parameters (data not shown); all parameters were comparable with control and/or baseline average ±2 SDs and/or within the range of normal variability for this species. The three IS animals exhibited changes in the CBC count after the onset of the IS regimen ( Figure S1 ). These changes initially emerged before vector dosing and were thus not related to the test article. Anomalies present in the three IS animals were a transient neutrophilic leukocytosis on day 0 and an anemia that resolved after MMF withdrawal on day 60. Blood chemistry was normal for the most part, except for a minimal increase in alanine aminotransferase (2.5-fold increase relative to baseline) in animal RA1404. This increase returned to baseline levels by day 90. All IS animals had low inorganic phosphate values, and two IS animals had low albumin levels. We believe these levels were caused by frequent diarrhea, which can lead to intestinal malabsorption.
CSF analysis revealed treatment-related changes. A mild mononuclear pleocytosis (5-30 cells/mL) occurred in most HD-treated animals and in one LD-treated animal ( Figures 1A-1D ; Table S3 ). The IS and vehicle control animals had normal CSF parameters throughout the study. The pleocytosis (mainly lymphocytes with fewer macrophages) appeared as early as day 14, peaked between days 21 and 45, and typically resolved by day 90. Only one animal had a second peak of pleocytosis at day 120. In some animals, the elevated CSF nucleated cells were inconsistently paralleled by a mild transient increase in CSF protein. We did not observe any changes in CSF glucose concentration.
Immune Responses to hIDUA and AAV9 Capsid
We evaluated serum and CSF samples for antibodies against hIDUA using an ELISA (Figure 2A ). Antibodies against hIDUA were detectable in the serum (dilution 1:1,000) and CSF (1:20) of all vector-treated animals that were not immune suppressed. The response was of similar intensity among LD and HD animals. IS completely ablated the formation of antibodies to hIDUA at the tested dilutions during the 90-day in-life phase of the study. Neutralizing antibodies (NAbs) to AAV9 emerged at levels that were similar across both non-IS dose cohorts. Peak titers reached 1:1,280-5,120 in the serum and 1:20-160 in the CSF of most animals ( Figure 2B ). IS markedly reduced the formation of AAV9 NAbs in serum, with levels ranging from 1:20 to 1:160.
We detected T cell responses to hIDUA peptide pools following vector administration in the peripheral blood mononuclear cells (PBMCs) of all HD and LD animals and in one of the three HD IS animals ( Figure 2C ; Table S4 ). T cell responses to AAV9 capsid occurred sporadically and with a low magnitude across all groups. T cell responses to the transgene product in the IS animals were less prevalent and occurred later compared with non-IS animals, likely reflecting MMF withdrawal on day 60. RA1404 had an earlier MMF withdrawal on day 35 and was maintained with rapamycin only until scheduled sacrifice. This animal did not exhibit any measurable T cell immune response.
Histopathology
Peripheral organs showed no gross or microscopic test article-related changes. Histologic findings related to the test article were visible in the dorsal root ganglia (DRG), the corresponding axons from dorsal www.moleculartherapy.org spinal cord white matter, and the trigeminal nerve ganglia. Tables S5  and S6 list and summarize the incidence and severity of the histopathology findings.
We observed minimal to mild neuronal cell body degeneration with mononuclear cell infiltration ( Figures 3A and 3B ) in at least one DRG and trigeminal nerve ganglia of all animals except one HD IS animal; note that the DRG and trigeminal nerve ganglia were collected only from animals in the second study. This finding was absent in the DRG of the vehicle control animal ( Figure 3C ). All spinal cord segments showed minimal to moderate axonopathy localized within the dorsal white matter tracts (i.e., axons projecting from DRG sensory neurons). This axonopathy was bilateral and characterized by dilated myelin sheaths with and without myelomacrophages, consistent with axonal degeneration ( Figures 3D and 3E ). Occasionally, axonal degeneration was also observed in the dorsal nerve roots of the spinal cord and, in one LD animal, in the sciatic nerve. This dorsal axonopathy was absent in the vehicle control ( Figure 3F ) but present in at least one spinal cord segment of all but one HD IS animal ( Figure 3G ). Overall, the incidence and severity of the DRG degeneration and axonopathy trended toward lower scores in the HD IS animals ( Figure 3G ). Additionally, we observed axonopathy in the spinal cord segment adjacent to the intrathecal injection site in all groups except the vehicle control group.
In the DRG, inflammatory cells were mostly CD20 + B lymphocytes and CD3 + T lymphocytes ( Figure 3H ). Overall, very few CD68 + mac-rophages were present (data not shown). Lymphocytes were clustered around hIDUA-positive transduced neurons and sometimes formed small inflammatory nodules replacing missing neurons (neuronophagia). Nuclei that were not positive for lymphocyte or monocyte markers were likely satellite cells that were activated to proliferate.
A few animals showed minimal focal mononuclear cell infiltrates in the leptomeninges of the brain. The brain parenchyma itself (frontal, occipital, parietal, and temporal cortices, cerebellum, hippocampus, and medulla), as well as the spinal cord gray matter, were within normal limits in all animals.
Vector Biodistribution
We extracted DNA from tissues as listed in Table 2 and quantified the vector genomes. The complete biodistribution with individual results is detailed in Table S7 . The average values per group are illustrated in Figure 4 . We detected AAV vector genomes throughout the brain, spinal cord, and DRG of all vector-treated animals and found that levels in the HD group were approximately 10 times higher than the LD group. In the HD groups, GCs were about 1 Â 10 5 GCs/mg DNA in the brain, spinal cord segments, and DRG without any notable differences between days 14, 90, and 180. Furthermore, we observed no discernable effect of the distance relative to the injection site in the spinal cord segments. Across all groups, the cerebellum contained the lowest copy numbers from the CNS. Vector GC levels were similar or trended higher in the DRG from HD IS animals compared with HD animals. The vector was significantly distributed to the peripheral organs, especially the liver, with GCs around 1 Â 10 6 GCs/mg DNA. We also recovered vector genomes from the lymphoid organs (spleen, lymph node, and bone marrow; 1 Â 10 4 to 1 Â 10 5 GCs/mg DNA). The eye, gonads, lungs, and thyroid exhibited the lowest vector distribution (1 Â 10 2 to 1 Â 10 3 GCs/mg DNA).
DISCUSSION
This study evaluated the safety of ICM administration of an AAV9 vector expressing hIDUA in nonhuman primates. Using a large-animal model and the intended clinical route of administration enabled us to assess toxicity related to both the vector and the injection procedure. We observed no adverse events associated with image-guided ICM injection and no histological lesions in vehicle-treated or day 14 vector-treated animals, supporting the safety of image-guided ICM injection.
Among vector-treated animals, we observed an unexpected toxicity consisting of asymptomatic degeneration of some sensory neuron cell bodies in the DRG and associated axons in the spinal cord and peripheral nerves. This toxicity was similar to the sensory ganglionitis that has been previously observed in piglets and juvenile nonhuman primates that were dosed intravenously with an AAV9 variant encoding human survival motor neuron 1; however, it had no clinical consequence, unlike what has been seen in piglets. 16 Interestingly, sensory neuron toxicity was absent in MPS I cats and MPS I dogs that were treated intrathecally with AAV9.fIDUA or AAV9.hIDUA, respectively, at doses similar to the nonhuman primate toxicology study. 12, 14 At higher doses, non-tolerized MPS I dogs treated with AAV9.hIDUA (1 Â 10 13 GCs/kg, translating to about 10fold higher dose than our nonhuman primates HD based on GCs/g of brain) developed a marked CSF pleocytosis, hindlimb weakness, and degeneration of lumbar motor neurons with infiltration of B and T lymphocytes; non-tolerized dogs treated with a similar dose to the ones used in our nonhuman primate studies (approximately 1 Â 10 11 GCs/g of brain) did not develop any neuronal or axonal degeneration. 14 To the best of our knowledge, no published reports exist of similar DRG toxicity in mice or rats dosed intrathecally with various AAV vectors. Rhesus macaques and piglets seem to be more sensitive to DRG toxicity. Hence, pigs or nonhuman primates would be useful models for assessing DRG toxicity with other intrathecal AAV programs. We do not know whether CSF pleocytosis is predictive of DRG toxicity because it did not strictly correlate with histological findings in the animals. Interestingly, CSF pleocytosis was observed as well in non-tolerized MPS I dogs treated with AAV9.hIDUA and was less pronounced in tolerized dogs. 14 The mechanisms responsible for vector-induced sensory neuropathy are currently undefined. We observed that CD3 + T cells were clustered around hIDUA-positive neurons, and we detected cellular immune responses against the hIDUA protein. However, these findings were still present in animals with pharmacologically suppressed T cell responses. Perhaps immune responses are not causative but worsen an initial injury; for instance, others have observed overexpression-induced neuronal toxicity in nonhuman primates after parenchymal injection of AAV expressing self-hexosaminidase under the control of a strong promoter similar to ours. 17 The immune response to the hIDUA protein is consistent with the relatively high immunogenicity of this protein and has been previously observed in murine, canine, and feline models of gene therapy, in addition to the high rate of antibody responses in MPS I patients treated with recombinant IDUA. [12] [13] [14] 18 Irrespective of the mechanism of DRG toxicity, the findings suggest that these cells were heavily transduced following ICM AAV9 administration. Previous studies have reported efficient transduction of DRG utilizing systemic or intrathecal AAV delivery. [19] [20] [21] [22] We currently do not know why sensory neurons are targeted using both routes of administration. DRG are outside of the blood-brain barrier and contain an area rich in neuronal cell bodies, which presents a high density of capillaries with a fenestrated endothelium. 23, 24 The porous endothelium of DRG capillaries at least partially explains the robust transduction of these cells following systemic AAV administration. However, peripheral axon targeting followed by retrograde trafficking to the cell body could also occur, which would explain the high transduction of lower motor neurons following systemic AAV delivery. 25 Likewise, anatomic factors could explain efficient targeting of DRG neurons following intrathecal AAV delivery. The axons of DRG neurons are directly exposed to CSF in the dorsal roots, thus providing a means for axonal transduction by vector delivered into the CSF. Moreover, the spinal subarachnoid space is contiguous with the extracellular fluid of the DRG, which potentially allows the vector to pass directly from the CSF to the soma of DRG neurons.
IFN-ϒ ELISPOT
The severe systemic toxicity that we observed recently in nonhuman primates following an intravenous delivery of high-dose AAV 16 was not detectable in these experiments despite the fact that the vector was substantially distributed outside of the CNS. This is not surprising given that the total dose of vector administered via ICM in this study is 50-fold lower than what we used in the intravenous studies. Instead, the toxicity we observed in this study was limited to minimal to moderate DRG neuron lesions. When comparing IS and non-IS vector-treated animals, our results suggest that IS can help alleviate the incidence and severity of the spinal cord and DRG test articlerelated findings. However, it is hard to draw any definitive conclusions due to study limitations, such as cohort size. We have shown in canine and feline models of MPS I that the rise of IDUA antibodies after delivering AAV9 gene therapy reduces but does not eliminate efficacy. 12, 14 An additional benefit of IS is the modulation of adaptive immune responses to the transgene product, including T cells and antibodies against hIDUA, which should improve the therapeutic index.
In sum, this study of intrathecal AAV9-delivered hIDUA in rhesus macaques demonstrated safety of the suboccipital vector administration procedure, as well as an overall positive benefit-risk profile, for a devastating disorder such as MPS I, and specifically Hurler syndrome. Our findings support close monitoring for sensory neuron toxicity in human studies. It will be essential to frequently evaluate sensory symptoms such as paresthesias or changes in sensations of pain, temperature, touch, or proprioception. Quantitative sensory testing may enable more rigorous evaluation of subtle sensory changes. In addition, gathering objective measures, such as sensory nerve conduction, may be informative.
MATERIALS AND METHODS
Animals
All animal procedures were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania. Rhesus macaques (Macaca mulatta) that screened negative for AAV9 NAbs were procured from Covance Research Products (Princeton, NJ, USA). Animals were housed in an Association for Assessment and Accreditation of Laboratory Animal Care International-accredited Nonhuman Primate Research Program facility at the University of Pennsylvania in stainless-steel squeeze back cages. Animals received varied enrichments such as food treats, visual and auditory stimuli, manipulatives, and social interactions.
Study Design
This paper combines two studies; an overview of the study design and animals is presented in Table 1 . We designed these studies to evaluate the safety, biodistribution, and pharmacology of two dose levels of the test article, a vector encoding a codon-optimized version of hIDUA for up to 180 days after administration via image-guided suboccipital puncture in rhesus macaques. The first study included 12 animals, and the second study included 10 animals, 3 of which were immunosuppressed via a combination of rapamycin and MMF. Both sexes were represented in all groups. Four macaques received the control article (artificial CSF) via suboccipital puncture. Eighteen rhesus macaques received the test article formulated in artificial CSF via suboccipital puncture. The animals were randomized to either receive an HD of 1 Â 10 13 GCs or an LD of 1 Â 10 12 GCs with or without IS, using an online randomized number generator (https://www. random.org). We collected blood and CSF as part of a general safety panel at time points indicated in Table 2 . We also evaluated the humoral response and T cell responses to the transgene product hIDUA and the AAV9 capsid. After completing the in-life phase of the study, macaques were necropsied and tissues were harvested for further evaluation. We performed histopathologic evaluation and biodistribution of the vector genome in a comprehensive list of tissues from the CNS, peripheral nervous system (PNS), and peripheral organs as summarized in Table 3 .
Test Article
The test article consisted of an AAV9 capsid packaging an expression construct with a hybrid promoter containing the cytomegalovirus enhancer with a chicken beta actin promoter (CB7), a chicken beta actin intron, a codon-optimized hIDUA transgene, and a rabbit beta-globulin polyadenylation signal. The expression construct was flanked by AAV serotype 2 inverted terminal repeats and was cloned in a plasmid containing a kanamycin resistance gene for manufacturing. The test article was manufactured under conditions as similar as possible to good manufacturing practice guidelines. The vector was produced by triple transfection of adherent HEK293 cells and purified from supernatant by affinity chromatography using a POROS CaptureSelect AAV9 resin (Thermo Fisher Scientific, Waltham, MA, USA), followed by anion exchange chromatography. Sterility of the test article was verified by direct immersion assay. Limulus amebocyte lysate and qPCR tests for endotoxin and mycoplasma, respectively, were negative. Vector titer by TaqMan PCR was 5.67 Â 10 13 GCs/mL. The purity of capsid proteins was 100%, as determined by SDS-PAGE analysis. Analytical ultracentrifugation indicated that the preparation contained 64% full vector particles. In vitro potency of the vector, assessed by IDUA enzyme expression, was confirmed to be similar to reference vector lots. The final product was diluted in Elliott's B Solution (Lukare Medical, Scotch Plain, NJ, USA) with 0.001% Pluronic F-68 (Thermo Fisher Scientific, Waltham, MA, USA). Dilutions were calculated using a standardized vector preparation form, and calculations were verified by designated personnel as indicated on the vector preparation forms. Unused vector preparations were archived and stored at À60 C to À80 C. 
ICM Injection Procedure
Anesthetized macaques were transferred from animal holding to the procedure room and placed on an X-ray table in the lateral decubitus position with the head flexed forward for CSF collection and dosing ICM. The site of injection was aseptically prepared. Using aseptic technique, a 21G-27G, 1-to 1.5-inch Quincke spinal needle (Becton Dickinson, Franklin Lakes, NJ, USA) was advanced into the suboccipital space until the flow of CSF was observed, and 1 mL of CSF was collected for baseline analysis. The needle was directed at the wider superior portion of the cisterna magna to avoid potential brainstem injury. Correct placement of needle was verified by fluoroscopy (OEC 9800 C-arm; GE Healthcare, Little Chalfont, UK). After CSF collection, a Luer access extension catheter was connected to the spinal needle to facilitate dosing of 180 mg/mL Iohexol contrast media (GE Healthcare, Little Chalfont, UK). After verifying needle placement, a syringe containing the test article (volume equivalent to 1 mL plus the syringe volume and linker dead space) was connected to the flexible linker and injected over 30 ± 5 s. The needle was removed, and direct pressure was applied to the puncture site.
Verification of correct placement of the needle using a computed tomography scanner and contrast injection is key to mitigate the risk for accidental puncture or injection into the brainstem. This procedure, when translated to patients, will be performed in neurointerventional radiology suites and will use both angiography and intrathecal contrast injection to prevent accidental puncture of large vessels or brainstem.
Immunosuppression A pilot study was conducted and demonstrated that orogastric gavage in chair-trained animals was a more reliable and reproducible method to achieve and maintain blood and plasma trough target levels when compared with treat-based voluntarily consumption. Animals were acclimated to the collar, pole capture, and chair restraint. Once acclimated, the animals were trained for insertion of an orogastric feeding tube and were then dosed through the feeding tube with a combination of commercially available IS drugs: a 200 mg/mL oral solution of MMF (CellCept; Roche Products) and 0.5, 1, or 2 mg coated tablets of rapamycin (Sirolimus, Rapamune; Greenstone) crushed in water. The IS regimen was initiated 3 weeks prior to intrathecal dosing of the test article. Rapamycin (0.75-2 mg/kg, once per day) and MMF (25-100 mg/kg, twice per day) dosages were adjusted to maintain a blood target trough level range of 2-3.5 mg/mL mycophenolic acid and 10-15 mg/L rapamycin. Rapamycin was used for the entirety of the study, whereas MMF was stopped on study day 60. Trough levels were monitored twice a week and IS doses were adjusted if the levels were either below or above the target range for two consecutive bleedings. Overall, rapamycin levels were steady and on target. MPA, the active metabolite of MMF, was below the target range of 2-3.5 mg/mL in RA1404 and had to be stopped earlier in this animal because of recurrent diarrhea (see Results).
Blood and CSF Analysis
Serum chemistry, hematology, coagulation, and CSF analyses were performed by the contract facility Antech GLP or Antech Diagnostics (Morrisville, NC, USA).
Immunology
Peripheral blood T cell responses against hIDUA and the AAV9 capsid were measured by interferon gamma (IFN-g) enzyme-linked immunosorbent spot (ELISPOT) assays according to previously published methods, 26 using peptide libraries specific for AAV9 capsid and the hIDUA transgene. Positive response criteria were >55 spot-forming units per 10 6 lymphocytes and three times the medium negative control upon no stimulation. In addition, T cell responses were assayed in lymphocytes that were extracted from spleen and bone marrow after necropsy on study day 90. NAbs against AAV9 capsid were measured in serum and CSF using an in vitro HEK293 cell-based assay as previously described. 27 NAb titers are reported as the reciprocal of the sample dilution that inhibits transduction of 50% of the cells. The limit of detection of the assay was 1:5 sample dilution. Antibodies to hIDUA were measured in serum (1:1,000 sample dilution) and CSF (1:20 sample dilution) as previously described. 13 Biodistribution DNA was extracted from tissues using QIAamp Mini Extraction kits (Cat. 51306; Qiagen). Biodistribution analysis was performed by TaqMan qPCR targeting a vector polyadenylation signal sequence. Assays results were reported as GCs/mg DNA.
Necropsy
All animal procedures were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania. Animals were euthanized with intravenous pentobarbital overdose, necropsied, and tissues harvested for comprehensive histopathologic examination. Table 3 lists tissues that were collected and examined histologically. For study RGX160822p, only select tissues were examined by the study pathologist, which included CNS and PNS system tissues, as well as gross lesions.
Histology
Tissues were fixed in formalin, paraffin embedded, sectioned, and stained with H&E according to standard protocols. Tissues were evaluated histologically and peer-reviewed by two board-certified veterinary anatomic pathologists. The severity of lesions was graded as follows: grade 1 (minimal histopathologic change from inconspicuous to barely noticeable, affecting less than approximately 10% of the tissue); grade 2 (mild histopathologic change that is noticeable but not prominent, affecting approximately 10%-25% of the tissue); grade 3 (moderate histopathologic change that is prominent but not a dominant feature, affecting approximately 25%-50% of the tissue); grade 4 (marked histopathologic change that is dominant but not an overwhelming feature, affecting approximately 50%-95% of the tissue); grade 5 (severe histopathologic change that is an overwhelming feature, affecting greater than approximately 95% of the tissue). Three segments of the spinal cord (cervical, thoracic, lumbar) and at least three DRG from each segment (cervical, thoracic, lumbar) were evaluated. To ease global interpretation and allow comparison between groups, we also present combined scores for the spinal cord and DRG findings, representing the sum of the severity grades in cervical, thoracic, and lumbar segments with a range of 0-15.
For immunofluorescence, paraffin sections were deparaffinized through a series of xylene and ethanol treatments, boiled in a microwave for 6 minutes in 10 mM citrate buffer (pH 6.0), and treated with blocking buffer (1% donkey serum in PBS + 0.2% Triton for 10 min) followed by incubation with primary (1 hr) and fluorescence-labeled secondary (45 min; Jackson Immunoresearch, West Grove, PA, USA) antibodies diluted in blocking buffer. For dual staining, the two primary and two secondary antibodies were mixed together. Sections were mounted in Vectashield with DAPI (Vector Laboratories, Burlingame, CA, USA) to stain nuclei. Primary antibodies were rabbit polyclonal against CD3 (A045229-2; Agilent Technologies, Santa Clara, CA, USA) and CD20 (PA5-16701; Life Technologies, Carlsbad, CA, USA) and a sheep polyclonal against IDUA (AF4119; R&D Systems, Minneapolis, MN, USA). 
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